NCT06963593View on ClinicalTrials.gov

Clinical Study on the Treatment of Anorexia and Cachexia in Advanced Gastric and Esophageal Cancer With Nanosized Megestrol Acetate Combined With Immunochemotherapy

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

August 31, 2027

Conditions
Advanced Gastroesophageal Cancer
Interventions
DRUG

Nanocrystal Megestrol Acetate in Combination with First-Line Standard Immuno-Chemotherapy Regimen

Megestrol Acetate Nanocrystal Oral Suspension Group: Nanocrystal Megestrol Acteate Oral Suspension (QD, up to 16 weeks from the initiation of immuno-chemotherapy) + PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)

DRUG

First-Line Standard Immuno-Chemotherapy Regimen

PD-1 inhibitor (Q3W, until PD) + Chemotherapy regimen (TP regimen or XELOX regimen or SOX regimen selected based on cancer type, Q3W, as per package insert)

All Listed Sponsors
lead

Peking University

OTHER